LBA45 - Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

E Van Cutsem,A Valderrama,Y.-J Bang,C Fuchs,K Shitara,Y.Y Janjigian,S Qin,T Larson,V Shankaran,S Stein,J.M Norquist,U Kher,S Shah,M Alsina

doi:10.1093/annonc/mdz394.036

LBA45 - Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

E Van Cutsem, A Valderrama + Show 12 more

Open Access

https://doi.org/10.1093/annonc/mdz394.036

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 5	License type: publisher-specific-oa

Affiliation: Seoul National University, Smilow Cancer Hospital, National Cancer Center Hospital East, Nanjing Brain Hospital, Autonomous University of Barcelona

#Combined Positive Score #Research Grant + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA45 - Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Full Text